Physician profile
Stephen Glasser
NPI 1912073214
$3,750.74
in general payments reported to CMS, 2019-2025
34 companies · $22.57 in 2025
The $22.57 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $947 · 2021: $1,155 · 2022: $90.06 · 2023: $363 · 2025: $22.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $363 · Food and Beverage: $22.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $363.00 |
| Food and Beverage | $22.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $381.87 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $360.53 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $322.63 | 2019-2022 | |
| Novo Nordisk INC | $268.07 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $267.02 | 2019-2020 | |
| Pfizer INC. | $254.40 | 2019-2021 | |
| Amgen INC. | $247.04 | 2019-2021 | |
| Lilly USA, LLC | $200.33 | 2020-2022 | |
| Abbvie INC. | $184.85 | 2020-2021 | |
| Tersera Therapeutics LLC | $163.00 | 2023 | |
| Amarin Pharma, INC. | $127.71 | 2019-2021 | |
| Glaxosmithkline, LLC. | $127.57 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $108.99 | 2019-2021 | |
| Astellas Pharma US INC | $100.97 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $64.60 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $57.71 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.10 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $41.95 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $39.22 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.23 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $37.35 | 2021 | |
| Boston Scientific Corporation | $36.83 | 2021 | |
| Endo Pharmaceuticals INC. | $35.93 | 2021 | |
| Allergan, INC. | $33.10 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.78 | 2019 | |
| Horizon Therapeutics Plc | $23.68 | 2021 | |
| Coopervision INC. | $22.57 | 2025 | Myday Contact Lens |
| Exelixis INC. | $22.36 | 2019 | |
| Medicure Pharma INC. | $20.98 | 2021 | |
| Eisai INC. | $20.79 | 2021 | |
| Nestle Healthcare Nutrition INC. | $17.83 | 2021 | |
| Daiichi Sankyo INC. | $16.40 | 2021 | |
| Ibsa Pharma INC. | $14.94 | 2021 | |
| Abbott Laboratories | $13.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Glasser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.